(ULTRA-)LONG-ACTING INSULIN ANALOGUES FOR PEOPLE WITH TYPE 1 DIABETES MELLITUS| Article
Compares the effects of long‐term treatment with (ultra‐)long‐acting insulin analogues to NPH insulin (neutral protamine Hagedorn) or another (ultra‐)long‐acting insulin analogue in people with type 1 diabetes mellitus.
GUIDELINES FOR INSULIN USE | Report
This tool aims to assist decision makers when formulating evidence-based recommendations on national clinical guidelines and reimbursement decisions.
INTERCHANGEABILITY OF BIOSIMILARS IN THE EUROPEAN UNION | Report
This report outlines European and United States guidelines on the interchangeability of biosimilars. It includes studies where people switched from an insulin reference product to a biosimilar and advice on the use of biosimilars in clinical practice.